Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH, Beelen KJ, Vincent AD, van der Noort V, van Diest PJ, Linn SC. Koornstra RH, et al. Among authors: van diest pj, van der noort v. Breast. 2015 Dec;24(6):705-12. doi: 10.1016/j.breast.2015.08.009. Epub 2015 Oct 1. Breast. 2015. PMID: 26429398 Clinical Trial.
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS). Badrising SK, et al. Among authors: van oort im, van voorthuizen t, van den eertwegh aj, van den berg hp, van der noort v. Oncology. 2016;91(5):267-273. doi: 10.1159/000448219. Epub 2016 Aug 20. Oncology. 2016. PMID: 27544669
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium. Cirkel GA, et al. Among authors: van den berkmortel f, van der noort v. JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202. JAMA Oncol. 2017. PMID: 27918762 Clinical Trial.
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
Lam SW, van der Noort V, van der Straaten T, Honkoop AH, Peters GJ, Guchelaar HJ, Boven E. Lam SW, et al. Among authors: van der straaten t, van der noort v. Pharmacol Res. 2018 Feb;128:122-129. doi: 10.1016/j.phrs.2017.08.005. Epub 2017 Aug 18. Pharmacol Res. 2018. PMID: 28827188 Clinical Trial.
Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.
Fransen van de Putte EE, Pos F, Doodeman B, van Rhijn BWG, van der Laan E, Nederlof P, van der Heijden MS, Bloos-van der Hulst J, Sanders J, Broeks A, Kerst JM, van der Noort V, Horenblas S, Bergman AM. Fransen van de Putte EE, et al. Among authors: van rhijn bwg, van der laan e, van der heijden ms, van der noort v. J Urol. 2019 Mar;201(3):478-485. doi: 10.1016/j.juro.2018.10.007. J Urol. 2019. PMID: 30321552
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, van der Noort V, Jager A, Sonke GS; SONIA study steering committee. van Ommen-Nijhof A, et al. Among authors: van zeijl cjj, van der noort v. BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1. BMC Cancer. 2018. PMID: 30458732 Free PMC article.
108 results